Medtronic has obtained FDA approval for its Simplera Sync glucose sensor, designed for use with the company’s MiniMed 780G insulin pumps. The new sensor will function as part of an advanced automated insulin delivery system, which is set to launch in a limited capacity this fall. CEO Geoff Martha highlighted that Simplera Sync, along with a new sensor being developed with Abbott, is expected to significantly boost Medtronic’s U.S. diabetes business. This development follows Medtronic’s recovery from an FDA warning letter, including the long-awaited approval for their 780G insulin pump.
The Simplera Sync represents an advancement in diabetes care, being smaller and eliminating the need for finger sticks or tape. The MiniMed 780G system features meal detection technology to regulate insulin delivery, even compensating for missed doses or underestimated carbohydrate intake, and supports glucose targets as low as 100 mg/dL. Further expansion is anticipated with plans to seek approval to use the 780G pump for individuals with Type 2 diabetes. The partnership with Abbott suggests a future where Medtronic devices will have enhanced compatibility with more advanced continuous glucose monitors (CGMs).
Medtronic’s recent FDA approval marks a significant step forward in its diabetes treatment technology. The company aims to provide improved and user-friendly solutions for people with diabetes while planning expansions and collaborations to maintain comprehensive and competitive care offerings.
